Stay updated on BA3021 in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the BA3021 in Head and Neck Cancer Clinical Trial page.

Latest updates to the BA3021 in Head and Neck Cancer Clinical Trial page
- Check3 days agoChange Detected- Revision tag updated from v3.2.0 to v3.3.2 on the page.SummaryDifference0.1%

- Check17 days agoChange DetectedRemoved: a banner/notice regarding government funding lapse and NIH operating status from the page. This deletion does not affect the actual study details, eligibility criteria, or reported outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check39 days agoChange DetectedStudy status updated to Completed with primary completion and study completion dates listed as 2025-09-22. Enrollment is shown as 42 across seven locations in the United States.SummaryDifference0.4%

- Check61 days agoChange DetectedThe page now includes a funding-status notice and a current operating status link, and updates the revision to v3.2.0 while removing the older Last Update Posted label and v3.1.0.SummaryDifference4%

- Check68 days agoChange DetectedNew Phase 2 Ozuriftamab Vedotin study added with current dates and 7 locations; older recruitment details, contacts, and Oregon-specific listings removed. Overall, page content now centers on the updated Phase 2 trial information.SummaryDifference8%

- Check82 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed, with no substantive content changes otherwise.SummaryDifference0.2%

Stay in the know with updates to BA3021 in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BA3021 in Head and Neck Cancer Clinical Trial page.